Literature DB >> 11920410

Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.

John P A Ioannidis1, Vassilios A Vassiliou, Haralampos M Moutsopoulos.   

Abstract

OBJECTIVE: Primary Sjögren's syndrome (SS) may lead to lymphoproliferative disease (LPD) and death in certain patients. We sought to determine the incidence and predictors of adverse long-term outcomes to achieve a rational predictive classification of the syndrome.
METHODS: Predictive modeling was performed in a cohort of 723 consecutive patients with primary SS (587 newly diagnosed [incident] cases and 136 prevalent cases).
RESULTS: During 4,384 person-years of followup, we recorded 39 deaths (7 due to lymphoma) and 38 diagnoses of LPD. The standardized mortality ratio was 1.15 (95% confidence interval [95% CI] 0.86-1.73) compared with the general population of Greece. In incident cases, the probability of LPD was 2.6% at 5 years and 3.9% at 10 years. Mortality rates were significantly higher in patients with low C4 levels at the first study visit (hazard ratio [HR] 4.39, 95% CI 2.18-8.83). LPD was independently predicted by the presence of parotid enlargement (HR 5.21, 95% CI 1.76-15.4), palpable purpura (HR 4.16, 95% CI 1.65-10.5), and low C4 levels (HR 2.40, 95% CI 0.99-5.83) at the first study visit. All patients who eventually developed lymphoma resulting in death during the followup period had either low C4 levels or palpable purpura at the first study visit. Training-validation split-cohort modeling confirmed the predictive importance of low C4 levels and palpable purpura, both of which were present in 20.9% of patients at their first visit.
CONCLUSIONS: In patients with primary SS, 1 in 5 deaths is attributable to lymphoma. The presence of palpable purpura and low C4 levels at the first visit adequately distinguishes high-risk patients (type I primary SS) from patients with an uncomplicated disease course (type II [low-risk] primary SS).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920410     DOI: 10.1002/art.10221

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  95 in total

Review 1.  Immunopathogenesis of Sjögren's syndrome.

Authors:  Andrea T Borchers; Stanley M Naguwa; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

2.  Earring lesions of the parotid tail.

Authors:  Bronwyn E Hamilton; Karen L Salzman; Richard H Wiggins; H Ric Harnsberger
Journal:  AJNR Am J Neuroradiol       Date:  2003-10       Impact factor: 3.825

Review 3.  Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjögren's syndrome.

Authors:  M R Kok; B J Baum; P P Tak; S R Pillemer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Large scale evidence and replication: insights from rheumatology and beyond.

Authors:  J P A Ioannidis
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

Review 5.  Rate, risk factors and causes of mortality in patients with Sjögren's syndrome: a systematic review and meta-analysis of cohort studies.

Authors:  Abha G Singh; Siddharth Singh; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2015-09-27       Impact factor: 7.580

6.  Characterization and Comparison of Patient Subgroups Suspicious for IgG4-Related Disease and Malignant Lymphoma in Patients Followed-up for Sjögren's Syndrome.

Authors:  Antónia Szántó; Katalin Szabó; Gábor Nagy; Csaba Molnár; Margit Zeher
Journal:  Pathol Oncol Res       Date:  2016-01-19       Impact factor: 3.201

Review 7.  Clinical, immunologic, and molecular factors predicting lymphoma development in Sjogren's syndrome patients.

Authors:  Michael Voulgarelis; Fotini N Skopouli
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 8.  Sjögren's syndrome--study of autoantigens and autoantibodies.

Authors:  John G Routsias; Athanasios G Tzioufas
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

9.  Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry.

Authors:  Caroline H Shiboski; Alan N Baer; Stephen C Shiboski; Mi Lam; Stephen Challacombe; Hector E Lanfranchi; Morten Schiødt; Penelope Shirlaw; Muthiah Srinivasan; Hisanori Umehara; Frederick B Vivino; Esen Akpek; Vatinee Bunya; Cristina F Vollenweider; John S Greenspan; Troy E Daniels; Lindsey A Criswell
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-01-03       Impact factor: 4.794

Review 10.  [Critical overview of outcome parameters for patients with primary Sjögren's syndrome].

Authors:  E Feist; A Hansen
Journal:  Z Rheumatol       Date:  2010-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.